Testing for kidney disease is routine in clinical practice. This review focuses on advances in clinical evaluation of the glomerular filtration rate and albuminuria and their use in detecting acute and chronic kidney disease, designing trials of disease progression, and predicting risk in clinical practice.
Funding and Disclosures
Disclosure forms provided by the authors are available with the full text of this article at NEJM.org.
This article was updated on June 2, 2022, at NEJM.org.
We thank our long-time colleagues Tom Greene, Mark J. Sarnak, Josef Coresh, Ron T. Gansevoort, Kunihiro Matsushita, and Hiddo J. Lambers-Heerspink for their contributions, Yingying Sang for providing risk predictions, and Ogechi M. Adingwupu for assistance in the preparation of an earlier version of the manuscript.
Print Subscriber? Activate your online access.